Abstracts Archive - Page 1399 of 2425 - ACR Meeting Abstracts

Abstract Number: 2902 • 2017 ACR/ARHP Annual Meeting
Inflammatory Arthritis Due to Immune Checkpoint Inhibitors: A Persistent Problem Requiring Immunosuppression
Laura Cappelli¹, Clifton O. Bingham III² and Ami A. Shah³, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as an important treatment for advanced malignancies. ICIs are a form of immunotherapy which block negative co-stimulation of…
Abstract Number: 2903 • 2017 ACR/ARHP Annual Meeting
Serum CC-Chemokine Ligand 18 Level Is a Potential Biomarker of Disease Activity in IgG4-Related Disease
Mitsuhiro Akiyama¹, Hidekata Yasuoka², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic disorder characterized by severe fibrosis in lesions. In previous reports, CC-chemokine ligand 18 (CCL18) level is a substantial…
Abstract Number: 2904 • 2017 ACR/ARHP Annual Meeting
Efficacy and Tolerance of TNF Alpha Inhibitor (TNFI) Treatment in Cardiac Sarcoidosis (CS)
Deborah Puyraimond-Zemmour¹, Catherine Chapelon-Abric², David Saadoun³, Diane Bouvry⁴, Marc Ruivard⁵, Marc Andre⁶, Laurent Perard⁷, Pascal Sève⁸ and Patrice Cacoub⁹, ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France, Paris, France, ²AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ³Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, ⁴Hopital Avicenne, Department of Pneumology, Bobigny, France, Bobigny, France, ⁵CHU Estaing, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ⁶CHU Montpied, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ⁷Department of Internal Medicine, Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France, ⁸Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Background/Purpose: CS is a life-threatening condition that accounts for 85% of sarcoidosis-related deaths in Japan and 13-25% in America. The objective is to evaluate the…
Abstract Number: 2905 • 2017 ACR/ARHP Annual Meeting
TET2 Mutation Is Significantly Associated with the Development of Autoimmune Disorder in Patients with Myelodysplastic Syndrome
Yoon-Jeong Oh¹, Dong-Yeop Shin², Sang Mee Hwang³, Eun Young Lee⁴, Yeong Wook Song⁵, Dong-Soon Lee³ and Jin Kyun Park⁶, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ³Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁴Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Koer, Seoul, Korea, Republic of (South), ⁶Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: Myelodysplastic syndrome (MDS) is characterized by ineffective hematopoiesis in bone marrow and peripheral cytopenia. Various genetic mutations contribute to MDS. Common mutations affect genes…
Abstract Number: 2906 • 2017 ACR/ARHP Annual Meeting
Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries
Dominick Sudano¹, C. Kent Kwoh², Lili Zhou³, Erin L. Ashbeck⁴ and Wei-Hsuan Lo-Ciganic⁵, ¹University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ⁴The University of Arizona Arthritis Center, Tucson, AZ, ⁵Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, Associate professor, TUCSON, AZ
Background/Purpose: Coccidioidomycosis (Cocci) is a fungal infection endemic to seven states in the US. Biologic response modifiers (BRMs) have been shown to increase the risk…
Abstract Number: 2907 • 2017 ACR/ARHP Annual Meeting
Salivary Gland Enlargement in IgG4-Related Disease Is Associated with Multiorgan Involvement and Higher Basal Disease Activity
Eduardo Martín Nares¹, Jacobo Guerrero Castillo², Arturo Angeles Angeles² and Gabriela Hernandez-Molina¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition which clinical spectrum encompasses single or multiple organ involvement. Enlargement of major and minor salivary glands is…
Abstract Number: 2908 • 2017 ACR/ARHP Annual Meeting
High Disease Activity Is a Predictor of Depression and Persistent Depression in Early Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Raman Joshi¹, Mohammad Movahedi², Bindee Kuriya³, Emmanouil Rampakakis⁴, Angela Cesta², Xiuying Li², Sandra Couto², John S. Sampalis⁵ and Claire Bombardier², ¹William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Sinai Health System, University of Toronto, Toronto, ON, Canada, ⁴JSS Medical Research, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada
Background/Purpose: The prevalence of depression among individuals with rheumatoid arthritis (RA) may be as high as 40% but persistence of depression over time is relatively…
Abstract Number: 2909 • 2017 ACR/ARHP Annual Meeting
Only Very High Radiographic Progression Affects HAQ-DI, Results from the Swiss Scqm Cohort
Ruediger Mueller¹, Reto Thalmann², Hendrik Schulze-Koops³, Nicole Graf⁴ and Johannes von Kempis², ¹Rheumatology, MD, St. Gallen, Switzerland, ²Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ⁴Graf Biostatistics, Winterthur, Switzerland
Background/Purpose: The aim of treatment of rheumatoid arthritis is to control disease activity and to inhibit joint damage. Progression of damage is analysed by conventional…
Abstract Number: 2910 • 2017 ACR/ARHP Annual Meeting
Comparison of Clinical and Ultrasound Measures of Disease Activity in a Large National ‘Real Life’ Cohort of RA Patients
Pascal Zufferey¹, Delphine Couvoisier², Hans Ruedi Ziswiler³, Laure Brulhart⁴, Giorgio Tamborrini⁵, Michael Nissen⁶, Adrian Ciurea⁷, Burkhard Moeller⁸, Maria Antonietta D'Agostino^9,10 and Axel Finckh², ¹Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ²geneva university hospital, Geneva, Switzerland, ³Osteorheuma, Bern, Switzerland, ⁴médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁵UZR, Basel, Switzerland, ⁶rheumatology, geneva university hospital, Geneva, Switzerland, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, ⁹Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, ¹⁰University of Paris, Paris, France
Background/Purpose: Clinical measures of disease activity, such as the DAS-score and ultrasound (US) scores of disease activity can be sometimes yield discordant results. Little research…
Abstract Number: 2911 • 2017 ACR/ARHP Annual Meeting
Low Appendicular Bone Mass Predicts Mortality in Patients with Rheumatoid Arthritis
Mark Edward Hall¹, Inmaculada del Rincon², Jose Felix Restrepo², Daniel F. Battafarano³, Jakob Algulin⁴ and Agustin Escalante², ¹Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Internal Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine, San Antonio Military Medical Center, San Antonio, TX, ⁴Sectra AB, Linköping, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) is a multi-system disease which causes joint damage and is associated with increased cardiovascular (CV) morbidity and osteoporosis. Our purpose is…
Abstract Number: 2912 • 2017 ACR/ARHP Annual Meeting
The Neural Correlates of Inflammation in RA: A Multi-Modal MRI Study
Andrew Schrepf¹, Chelsea Cummiford¹, Eric Ichesco¹, Tony Larkin¹, Steven E. Harte¹, Richard E. Harris¹, Alison Murray², Gordon Waiter³, Daniel J. Clauw⁴ and Neil Basu⁵, ¹Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ²Aberdeen Brain Imaging Center, University of Aberdeen, Aberdeen, United Kingdom, ³Aberdeen Brain Imaging Centre, University of Aberdeen, Aberdeen, United Kingdom, ⁴Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁵Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: Inflammation is the hallmark of disease activity in rheumatoid arthritis (RA). RA is characterized by fatigue and cognitive/affective disturbances, and these symptoms often worsen…
Abstract Number: 2913 • 2017 ACR/ARHP Annual Meeting
the Periodontal Pathogen Aggregatibacter Actinomycetemcomitans Is Associated with Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis
Jon T. Giles¹, Jesper Reinholdt², Joan Bathon³, Felipe Andrade⁴ and Maximilian F. Konig⁵, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The oral pathogen Aggregatibacter actinomycetemcomitans (Aa) generates citrullinated proteins targeted by autoantibodies in RA through its pore-forming toxin leukotoxin A (LtxA). Aa-derived LtxA is…
Abstract Number: 2914 • 2017 ACR/ARHP Annual Meeting
Anti-CCP Antibody Levels Are Elevated in Cervicovaginal Fluid in Association with Local Inflammation in Premenopausal Women without RA
Sonia Khatter¹, Heather Berens-Norman², Courtney Anderson¹, Justin August¹, Marie L. Feser¹, Chelsie Fleischer¹, Ashley Visser¹, Jill M. Norris³, V. Michael Holers¹, Kevin D. Deane¹ and M. Kristen Demoruelle¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: Data support that anti-CCP antibodies likely originate at a mucosal site prior to the onset of inflammatory arthritis (IA) in the development of RA.…
Abstract Number: 2915 • 2017 ACR/ARHP Annual Meeting
Increased Expression of Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti-Maa Antibody in Rheumatoid Arthritis-Interstitial Lung Disease
Bryant R. England¹, Geoffrey M. Thiele², Michael J. Duryee³, Dana P. Ascherman⁴, Liron Caplan⁵, M. Kristen Demoruelle⁶, Kevin D. Deane⁵ and Ted R. Mikuls⁷, ¹Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁷Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Generated under oxidative stress, malondialdehyde-acetaldehyde adducts (MAA), and antibody responses to MAA appear to facilitate loss of immune tolerance and generate pro-inflammatory responses in…
Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting
The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², R.J. Goekoop³, I Speyer⁴, TWJ Huizinga¹, CF Allaart¹, REM Toes¹ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Haga Hospital, The Hague, Netherlands, ⁴Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].